Clinical Trial Update: Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating alpelisib with paclitaxel in PIK3CA-altered gastric cancer is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Stomach Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Solid Tumor, Stomach Cancer | Phase 1, Phase 2 | Status: UNKNOWN